Mezigdomide (CC-92480)

Mezigdomide (CC-92480) is Bristol-Myers Squibb's next-generation cereblon E3 ligase modulator (CELMoD), engineered to degrade the same myeloma-driving transcription factors that lenalidomide and pomalidomide target, but faster and deeper [1]. It is in Phase 3 for relapsed/refractory multiple myeloma across two SUCCESSOR trials. SUCCESSOR-2 read out in Lancet 2026 with a hazard ratio of 0.48 for progression-free survival (52% reduction in progression risk) and median PFS of 18.0 versus 8.3 months, a definitive positive result [2]. The commercial question has narrowed from whether mezigdomide works to whether a more potent IMiD analog can hold market share against bispecific T-cell engagers, CAR-T, and generic pomalidomide once SUCCESSOR-1 reads out.

Novel small molecule, never approved, currently Phase 3. Mezigdomide originated at Celgene as CC-92480 and moved to BMS after the 2019 acquisition. It carries no publicly disclosed FDA breakthrough or accelerated approval designation, though multiple myeloma indications historically qualify for orphan drug status and FDA orphan drug status for mezigdomide specifically is not confirmed in the public Orphan Drug Product designation database as of writing [3]. SUCCESSOR-2 (NCT05372354) has read out in Lancet 2026, testing the mezigdomide + carfilzomib + dexamethasone (MeziKd) triplet against carfilzomib + dexamethasone (Kd) in patients relapsed after 1 to 3 prior lines including lenalidomide [2]. The readout was decisively positive: hazard ratio 0.48 (95% CI 0.36 to 0.63, p<0.0001), median PFS 18.0 versus 8.3 months, overall response rate (ORR) 80.2% versus 53.4%, and complete response or better in 26.7% versus 8.9% of patients [2]. SUCCESSOR-1 (NCT05519085), a Phase 3 comparing MEZIVd (mezigdomide + bortezomib + dexamethasone) against PVd (pomalidomide + bortezomib + dexamethasone) in 810 patients, is still enrolling with progression-free survival as the primary endpoint [4]. Estimated primary completion is 2027, with an interim readout likely at ASH December 2026 and primary readout likely at ASH December 2027. Regulatory submissions on the SUCCESSOR-2 dataset are the near-term catalyst; SUCCESSOR-1 will determine whether mezigdomide can displace pomalidomide as backbone IMiD in earlier lines. One caveat on the record: NCT02343042, sometimes linked to mezigdomide in aggregated databases, is a Karyopharm-sponsored selinexor umbrella that lists mezigdomide as one of many combination arms, not a mezigdomide-led registrational study.

Multiple myeloma cells depend on two transcription factors called Ikaros (IKZF1) and Aiolos (IKZF3), which act like master switches keeping the cancerous plasma cells alive and dividing. Cereblon is a natural cellular disposal tag: it is the substrate-recognition arm of an E3 ubiquitin ligase, meaning it grabs proteins and marks them for the cell's shredder [5]. Lenalidomide and pomalidomide are molecular glues that force cereblon to grab Ikaros and Aiolos and destroy them, which kills myeloma cells. Mezigdomide is the same trick, sharpened: it binds cereblon in a geometry that pulls in Ikaros and Aiolos more efficiently, so degradation is deeper and faster in preclinical and Phase 1 models than either older IMiD [1][6]. The mechanism is as validated as any target in oncology, since two blockbusters (Revlimid and Pomalyst) have generated tens of billions in cumulative revenue on the same axis, with Revlimid peaking at roughly $12B annually before loss of exclusivity and Pomalyst still generating multi-billion revenue [6]. The open question is not whether cereblon-mediated Ikaros degradation works, but whether more of it translates into better clinical outcomes in patients whose myeloma has already been selected for resistance by prior IMiD exposure. SUCCESSOR-2 has now answered that in the affirmative in the lenalidomide-exposed relapsed setting.

SUCCESSOR-2 (NCT05372354) randomized patients with relapsed/refractory multiple myeloma who had received 1 to 3 prior lines including a lenalidomide-containing regimen to mezigdomide + carfilzomib + dexamethasone (MeziKd) versus carfilzomib + dexamethasone (Kd) alone, with progression-free survival as the primary endpoint [2]. The published results establish a large effect: hazard ratio 0.48 (95% CI 0.36 to 0.63), median PFS 18.0 versus 8.3 months, ORR 80.2% versus 53.4%, and CR or better in 26.7% versus 8.9% [2]. Adding a third agent versus a doublet control makes the design mechanistically favorable to the experimental arm, but the magnitude of separation exceeds what add-on effects alone typically produce and represents a genuine efficacy signal. SUCCESSOR-1 (NCT05519085) is the harder comparator, pitting MEZIVd head-to-head against PVd in 810 patients, isolating the CELMoD-versus-IMiD substitution effect [4]. This is the trial that answers whether mezigdomide is genuinely a next-generation improvement or a marginal me-too against the current benchmark. Phase 1/2 combination work with T-cell engagers and CAR-T backbones is also underway across investigator-initiated and industry-sponsored programs, including a Memorial Sloan Kettering revumenib combination in leukemia [7], signaling BMS is not betting the franchise on the myeloma monotherapy narrative alone.

Our model estimates a 27% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 57%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by an unusually multi-arm design (12 arms); it is held back by the sponsor's thin or weak approval record, its few secondary endpoints, and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is concentrated in SUCCESSOR-1: pomalidomide is a genuinely active drug in relapsed myeloma, and if the PFS delta versus MEZIVd is small, the commercial case for switching becomes fragile once pomalidomide loses composition-of-matter protection and generics enter (pomalidomide LOE begins mid-decade, mezigdomide composition-of-matter is expected to run into the mid-2030s given the 2019-era filings, though the exact date is not disclosed and should be confirmed against orange-book or PatBase records before modeling). Safety risk is class-based but larger in magnitude than earlier IMiDs: SUCCESSOR-2 Phase 3 data show grade 3 to 4 neutropenia in 61.1% of MeziKd patients versus 9.1% on Kd, a 6.7x increase, and grade 3 to 4 infections in 34.0% versus 15.6% [2]. These are real-world adherence and hospitalization risks that will shape formulary decisions, growth factor support protocols, and patient selection criteria. Thromboembolism remains a class concern requiring prophylaxis. Commercial risk is the harder problem: the relapsed myeloma market is being reshaped by BCMA and GPRC5D bispecifics (teclistamab, talquetamab, elranatamab) and CAR-T (cilta-cel, ide-cel), all of which are pulling market share away from small-molecule triplets in the later lines where mezigdomide would slot in. Even a successful readout leaves BMS defending mezigdomide's positioning against its own bispecifics. The IMiD franchise ceiling to defend is meaningful: Revlimid peaked near $12B annually and Pomalyst adds several billion more, so even modest share retention through a next-generation successor is commercially material. Execution risk is low given BMS's myeloma commercial infrastructure, though enrollment competition with the same bispecific and CAR-T trials is a real friction point.

De-risked franchise extension, no longer speculative. SUCCESSOR-2 has already cleared the threshold this writeup previously set as the bar for genuine next-generation IMiD positioning. The hazard ratio (HR) measures relative risk of disease progression over time: an HR of 0.48 means the mezigdomide arm cut the progression rate by 52% versus control, which is exceptional in relapsed myeloma. That result reframes SUCCESSOR-1 from a bet on the molecule to a bet on the head-to-head margin versus pomalidomide + bortezomib + dexamethasone (PVd). An HR below 0.70 in SUCCESSOR-1 would justify positioning mezigdomide as a Revlimid/Pomalyst replacement and unlock earlier-line combination development. An HR of 0.75 to 0.90 would be a technical win but a commercial disappointment given the encroachment of bispecifics and CAR-T. For BMS, mezigdomide matters as a lifecycle extension of the Revlimid/Pomalyst franchise that is losing exclusivity, and as a partner molecule for its own bispecific programs where combining a T-cell engager with a CELMoD is mechanistically attractive [9]. Watch for SUCCESSOR-1 interim data at ASH December 2026 and primary readout at ASH December 2027, alongside BMS Q4 2026 and 2027 earnings calls for regulatory-submission timing on the SUCCESSOR-2 dataset. The near-term catalyst calendar is dense enough that this node deserves active tracking rather than passive monitoring, but the base case is now positive rather than uncertain.